temozolomide has been researched along with Cell Transformation, Neoplastic in 28 studies
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide (TMZ) is a promising chemotherapeutic agent for treating glioblastomas." | 7.80 | miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. ( Chen, J; Fu, X; Jiang, D; Shi, L; Wan, Y; Wang, Z, 2014) |
| "The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment." | 7.77 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K, 2011) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent but the efficacy is limited by intrinsic and acquired resistance in GBM." | 5.40 | Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells. ( Chen, YS; Chen, ZP; Guan, S; Guo, CC; Li, WP; Li, WY; Mou, YG; Sai, K; Wang, J; Yang, QY, 2014) |
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | 5.35 | Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| "An insufficient oxygen supply within the intratumoral environment, also known as hypoxia, induces glioblastoma multiforme (GBM) invasion, stemness, and temozolomide (TMZ) drug resistance." | 4.12 | Hypoxia-inducible lncRNA MIR210HG interacting with OCT1 is involved in glioblastoma multiforme malignancy. ( Chen, KC; Ho, KH; Liu, AJ; Shih, CM, 2022) |
| "The incidence, risk factors, and outcomes of low-grade glioma patients who undergo malignant transformation (MT) in the era of temozolomide are not well known." | 3.88 | Risk Factors for Malignant Transformation of Low-Grade Glioma. ( Ahluwalia, MS; Barnett, GH; Chao, ST; Jia, X; Kotecha, R; Leyrer, CM; Murphy, ES; Parsons, M; Peereboom, DM; Prayson, RA; Stevens, GHJ; Suh, JH; Vogelbaum, MA; Yu, JS, 2018) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent for treating glioblastomas." | 3.80 | miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. ( Chen, J; Fu, X; Jiang, D; Shi, L; Wan, Y; Wang, Z, 2014) |
| "Isocitrate dehydrogenase 1 (IDH1) mutations occur in most lower grade glioma and not only drive gliomagenesis but are also associated with longer patient survival and improved response to temozolomide." | 3.80 | Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. ( Mukherjee, J; Ohba, S; Pieper, RO; See, WL, 2014) |
| "The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment." | 3.77 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K, 2011) |
| "Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome." | 2.58 | Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). ( Lenders, N; McCormack, A, 2018) |
| "Atypical pituitary adenomas (APAs) are aggressive tumors, harboring a Ki-67 (MIB-1) staining index of 3% or more, and positive immunohistochemical staining for p53 protein, according to the World Health Organization (WHO) classification in 2004." | 2.50 | Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. ( Hirohata, T; Ishii, Y; Matsuno, A, 2014) |
| "Our case exhibited atypical central neurocytoma with an initially elevated MIB-1 labeling index (25-30 %)." | 1.40 | Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation. ( Barzo, P; Cserhati, A; Fodor, E; Hideghety, K; Mozes, P; Szanto, E; Tiszlavicz, L, 2014) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent but the efficacy is limited by intrinsic and acquired resistance in GBM." | 1.40 | Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells. ( Chen, YS; Chen, ZP; Guan, S; Guo, CC; Li, WP; Li, WY; Mou, YG; Sai, K; Wang, J; Yang, QY, 2014) |
| "We developed a mouse model of Lynch syndrome (Lgr5-CreERT2;Msh2(flox/-) mice) and found that environmental factors can modify the number and mutability of the MMR-deficient stem cells." | 1.40 | Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome. ( Cantelli, E; De Vries, S; Dekker, M; Delzenne-Goette, E; Plug, M; Song, JY; Te Riele, H; Van Der Wal, A; Van Gerwen, B; Wojciechowicz, K, 2014) |
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | 1.35 | Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.14) | 29.6817 |
| 2010's | 24 (85.71) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, KH | 1 |
| Shih, CM | 1 |
| Liu, AJ | 1 |
| Chen, KC | 1 |
| Feng, SW | 1 |
| Wu, ZS | 1 |
| Chiu, YL | 1 |
| Huang, SM | 1 |
| Xu, B | 1 |
| Ye, MH | 1 |
| Lv, SG | 1 |
| Wang, QX | 1 |
| Wu, MJ | 1 |
| Xiao, B | 1 |
| Kang, CS | 1 |
| Zhu, XG | 1 |
| Xue, W | 1 |
| Du, X | 1 |
| Wu, H | 1 |
| Liu, H | 1 |
| Xie, T | 1 |
| Tong, H | 1 |
| Chen, X | 1 |
| Guo, Y | 1 |
| Zhang, W | 1 |
| Lenders, N | 1 |
| McCormack, A | 1 |
| Murphy, ES | 1 |
| Leyrer, CM | 1 |
| Parsons, M | 1 |
| Suh, JH | 1 |
| Chao, ST | 1 |
| Yu, JS | 1 |
| Kotecha, R | 1 |
| Jia, X | 1 |
| Peereboom, DM | 1 |
| Prayson, RA | 1 |
| Stevens, GHJ | 1 |
| Barnett, GH | 1 |
| Vogelbaum, MA | 1 |
| Ahluwalia, MS | 1 |
| Oliva, CR | 1 |
| Halloran, B | 1 |
| Hjelmeland, AB | 1 |
| Vazquez, A | 1 |
| Bailey, SM | 1 |
| Sarkaria, JN | 1 |
| Griguer, CE | 1 |
| Sa, JK | 1 |
| Choi, SW | 1 |
| Zhao, J | 1 |
| Lee, Y | 1 |
| Zhang, J | 1 |
| Kong, DS | 1 |
| Choi, JW | 1 |
| Seol, HJ | 1 |
| Lee, JI | 1 |
| Iavarone, A | 1 |
| Rabadan, R | 1 |
| Nam, DH | 2 |
| Furuta, T | 1 |
| Nakada, M | 1 |
| Misaki, K | 1 |
| Sato, Y | 1 |
| Hayashi, Y | 1 |
| Nakanuma, Y | 1 |
| Hamada, J | 1 |
| Mozes, P | 1 |
| Szanto, E | 1 |
| Tiszlavicz, L | 1 |
| Barzo, P | 1 |
| Cserhati, A | 1 |
| Fodor, E | 1 |
| Hideghety, K | 1 |
| Auffinger, B | 1 |
| Tobias, AL | 1 |
| Han, Y | 1 |
| Lee, G | 1 |
| Guo, D | 1 |
| Dey, M | 1 |
| Lesniak, MS | 1 |
| Ahmed, AU | 1 |
| Chen, J | 1 |
| Fu, X | 1 |
| Wan, Y | 1 |
| Wang, Z | 1 |
| Jiang, D | 1 |
| Shi, L | 1 |
| Sai, K | 1 |
| Li, WY | 1 |
| Chen, YS | 1 |
| Wang, J | 2 |
| Guan, S | 1 |
| Yang, QY | 1 |
| Guo, CC | 1 |
| Mou, YG | 1 |
| Li, WP | 1 |
| Chen, ZP | 1 |
| Ohba, S | 1 |
| Mukherjee, J | 1 |
| See, WL | 1 |
| Pieper, RO | 1 |
| Wojciechowicz, K | 1 |
| Cantelli, E | 1 |
| Van Gerwen, B | 1 |
| Plug, M | 1 |
| Van Der Wal, A | 1 |
| Delzenne-Goette, E | 1 |
| Song, JY | 1 |
| De Vries, S | 1 |
| Dekker, M | 1 |
| Te Riele, H | 1 |
| Yeom, SY | 1 |
| Park, C | 1 |
| Zhang, RR | 1 |
| Pointer, KB | 1 |
| Kuo, JS | 1 |
| Dempsey, RJ | 1 |
| Hirohata, T | 1 |
| Ishii, Y | 1 |
| Matsuno, A | 2 |
| Riva, G | 1 |
| Butta, V | 1 |
| Cilibrasi, C | 1 |
| Baronchelli, S | 1 |
| Redaelli, S | 1 |
| Dalprà, L | 1 |
| Lavitrano, M | 1 |
| Bentivegna, A | 1 |
| Rotta, JM | 1 |
| de Oliveira, MF | 1 |
| Reis, RC | 1 |
| Botelho, RV | 1 |
| Kushner, BH | 1 |
| Laquaglia, MP | 1 |
| Kramer, K | 1 |
| Modak, S | 1 |
| Cheung, NK | 1 |
| Zoeller, GK | 1 |
| Brathwaite, CD | 1 |
| Sandberg, DI | 1 |
| Murakami, M | 1 |
| Mizutani, A | 1 |
| Asano, S | 1 |
| Katakami, H | 1 |
| Ozawa, Y | 1 |
| Yamazaki, K | 1 |
| Ishida, Y | 1 |
| Takano, K | 1 |
| Okinaga, H | 1 |
| Komatsu, F | 1 |
| Kawaguchi, H | 1 |
| Tsugu, H | 1 |
| Oshiro, S | 1 |
| Komatsu, M | 1 |
| Fukushima, T | 1 |
| Nabeshima, K | 1 |
| Inoue, T | 1 |
| Yang, YP | 1 |
| Chien, Y | 1 |
| Chiou, GY | 1 |
| Cherng, JY | 1 |
| Wang, ML | 1 |
| Lo, WL | 1 |
| Chang, YL | 1 |
| Huang, PI | 1 |
| Chen, YW | 1 |
| Shih, YH | 1 |
| Chen, MT | 1 |
| Chiou, SH | 1 |
| Luo, Y | 1 |
| Dallaglio, K | 1 |
| Chen, Y | 1 |
| Robinson, WA | 1 |
| Robinson, SE | 1 |
| McCarter, MD | 1 |
| Gonzalez, R | 1 |
| Thompson, DC | 1 |
| Norris, DA | 1 |
| Roop, DR | 1 |
| Vasiliou, V | 1 |
| Fujita, M | 1 |
| Morana, G | 1 |
| Piccardo, A | 1 |
| Garrè, ML | 1 |
| Nozza, P | 1 |
| Consales, A | 1 |
| Rossi, A | 1 |
| Tentori, L | 1 |
| Vergati, M | 1 |
| Muzi, A | 1 |
| Levati, L | 1 |
| Ruffini, F | 1 |
| Forini, O | 1 |
| Vernole, P | 1 |
| Lacal, PM | 1 |
| Graziani, G | 1 |
2 reviews available for temozolomide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Topics: Adenoma; Animals; Cell Transformation, Neoplastic; Dacarbazine; Humans; Pituitary Neoplasms; Temozol | 2018 |
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Topics: Adenoma; Administration, Oral; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; C | 2014 |
26 other studies available for temozolomide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Hypoxia-inducible lncRNA MIR210HG interacting with OCT1 is involved in glioblastoma multiforme malignancy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug | 2022 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma.
Topics: Adult; Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transfor | 2017 |
Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment.
Topics: Animals; Bevacizumab; Cell Line, Tumor; Cell Transformation, Neoplastic; Contrast Media; Drug Resist | 2017 |
Risk Factors for Malignant Transformation of Low-Grade Glioma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents | 2018 |
IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neo | 2018 |
Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.
Topics: Adult; Aged; Antigens, Neoplasm; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; | 2019 |
Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevaci | 2014 |
Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation.
Topics: Adult; Brain Neoplasms; Cell Transformation, Neoplastic; Cerebrospinal Fluid; Chemotherapy, Adjuvant | 2014 |
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Brain Neop | 2014 |
miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Cell Transformation, Neoplastic; Dacarbazine; | 2014 |
Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Transformation, Neopla | 2014 |
Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; DNA Damage; DNA Repair; Drug Resista | 2014 |
Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Topics: Adenocarcinoma; Adenoma; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Colorectal Ne | 2014 |
RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Shape; Cell Survival; Cell Transformation, | 2016 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, A | 2017 |
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Child; Combined Modality Therapy; Dacarbazine; F | 2008 |
Malignant transformation of an optic pathway glioma without prior radiation therapy.
Topics: Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; Chemotherapy, Adjuvant; Child, P | 2010 |
A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Cell Transformation, Neoplastic; Dacarbazine; DNA Modi | 2011 |
Radiation-induced astrocytoma with rapid malignant transformation: case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Basal Ganglia; Brain Neoplasms; Cell Transformation, | 2011 |
Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.
Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Transformation, Neoplastic; Dacarbazine; Down-Reg | 2012 |
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosi | 2012 |
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treate
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Antigens, Polyomavirus Transforming; Antineoplastic Agent | 2005 |